Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9382231 Bipyrazole derivatives as JAK inhibitors

Patent 9382231 was granted and assigned to Incyte on July, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Incyte

Current Assignee

Incyte

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9382231

Patent Inventor Names

Ding-Quan Qian0

Jincong Zhuo0

Song Mei0

Yun-Long Li0

Date of Patent

July 5, 2016

Patent Application Number

14279929

Date Filed

May 16, 2014

Patent Citations Received

‌

US Patent 12071439 Process and intermediates for preparing a JAK inhibitor

‌

US Patent 11992490 Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)

‌

US Patent 11685731 Processes of preparing a JAK1 inhibitor

‌

US Patent 11957661 JAK1 pathway inhibitors for the treatment of vitiligo

‌

US Patent 11905275 Bipyrazole derivatives as JAK inhibitors

‌

US Patent 11905292 Process and intermediates for preparing a JAK inhibitor

‌

US Patent 11833152 JAK1 pathway inhibitors for the treatment of cytokine-related disorders

Patent Primary Examiner

‌

Kamal Saeed

Patent abstract

The present invention provides compounds of Formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9382231 Bipyrazole derivatives as JAK inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API